Afuco™ Anti-IL6R ADCC Therapeutic Antibody (Satralizumab), ADCC Enhanced

This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to IL6R. Satralizumab is a human monoclonal antibody that can be potentially used in the treatment of Neuromyelitis optica (NMO).
Supplier Creative Biolabs
Product # AFC-TAB-032ML
Pricing Inquiry
Host Human
Target IL6R
Species Reactivity Human
Type ADCC enhanced antibody
Applications ELISA, IHC, FC, IP, IF, FuncS
Storage Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.
Feedback